

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Weirton Medical Center</p> <p>2. 601 Colliers Way Weirton, West Virginia 26062-5091</p>	<p>In accordance with the letter dated July 25, 2008,</p> <p>3. License number 47-17567-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date July 31, 2013</p> <hr/> <p>5. Docket No. 030-12977 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.500</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (ADAC Model Vantage)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1.5 curies</p> <p>D. 300 millicuries per source and 1200 millicuries total</p>
--	---	--

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
  - D. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

**CONDITIONS**

- 10. Licensed material may be used or stored only at the licensee's facilities located at 601 Colliers Way, Weirton, West Virginia.
- 11. The Radiation Safety Officer for this license is Mark T. Perna, M.S.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
47-17567-01

Docket or Reference Number  
030-12977

Amendment No. 28

12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Peter Aragones, M.D.	35.100; 35.200; 35.300; 35.500
Young J. Lee, M.D.	35.100; 35.200; 35.300; 35.500
John J. DeFilippo, M.D.	35.100; 35.200; 35.300; 35.500
Gary Loh, M.D.	35.100; 35.200; 35.300; 35.500
Eric R. Balzano, M.D.	35.100; 35.200
Mark L. Benson, M.D.	35.100; 35.200
William Lee Noble, II, M.D.	35.100; 35.200
Vincent J. Caruso, M.D.	35.100; 35.200
Michael J. Maroney, M.D.	35.100; 35.200
Carter A. Kenamond, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction
Thomas Neis, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
47-17567-01

Docket or Reference Number  
030-12977

Amendment No. 28

Authorized Users

Material and Use

Michael L. Slaysman, M.D.

35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

Terry L. Stake, M.D.

35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

Eric William Irwin, M.D.

35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
47-17567-01Docket or Reference Number  
030-12977

Amendment No. 28

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated January 10, 2003 [ML030240032]
  - B. Letter dated July 14, 2003 [ML032030139]
  - C. Letter dated May 25, 2004 [ML041700596]



For the U.S. Nuclear Regulatory Commission

Date September 30, 2008

By

***Original signed by Willie J. Lee***

---

Willie J. Lee  
Medical Branch  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406